Sp1 and Smad3 are required for high glucose-induced p21WAF1 gene transcription in LLC-PK1 cells

Journal of Cellular Biochemistry

Volumn 102, Issue 5, 2007, Pages 1190-1201

  Chuang, Tsai Der ^a   Guh, Jinn Yuh ^a   Chiou, Shean Jaw ^a   Chen, Hung Chun ^a   Hung, Wen Chun ^b   Chuang, Lea Yea ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Diabetic nephropathy; Hypertrophy; p21WAF1; Smad3; Sp1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; GLUCOSE; MESSENGER RNA; REGULATOR PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1;

ANIMAL CELL; ARTICLE; ATTENUATION; CELL CULTURE; CELL STRAIN; DNA BINDING; GENE DELETION; GENETIC TRANSCRIPTION; HYPERTROPHY; KIDNEY CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ANIMALS; BETA-GALACTOSIDASE; CELL CULTURE TECHNIQUES; CULTURE MEDIA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE DELETION; GLUCOSE; LLC-PK1 CELLS; LUCIFERASES; PLASMIDS; RNA, SMALL INTERFERING; SMAD3 PROTEIN; SP1 TRANSCRIPTION FACTOR; SWINE; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 36849000409     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21346     Document Type: Article

References (44)

1. Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ. 1999. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56:1691-1699.
2. Chae YM, Park KK, Magae J, Lee IS, Kim CH, Kim HC, Hong S, Lee JG, Choi IJ, Kim HS, Min KS, Lee IK, Chang YC. 2004. Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochem Biophys Res Commun 319:550-555.
3. Chen S, Hoffman BB, Lee JS, Kasama Y, Jim B, Kopp JB, Ziyadeh FN. 2004. Cultured tubule cells from TGF-betal null mice exhibit impaired hypertrophy and fibronectin expression in high glucose. Kidney Int 65:1191-1204.
4. Chuang LY, Guh JY. 2001. Extracellular signals and intracellular pathways in diabetic nephropathy. Nephrology 6:165-172.
5. WAF1 expression in LLC-PK1 cells. Kidney Int 71:867-874.
6. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. 1995a. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549.
7. Datto MB, Yu Y, Wang XF. 1995b. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J Biol Chem 270:28623-28628.
8. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. 2002. Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem 277:823-829.
9. Fan YP, Weiss RH. 2004. Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol 15:575-584.
10. Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S. 2003. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305:1002-1007.
11. Fujita H, Omori S, Ishikura K, Hida M, Awazu M. 2004. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 286:F120-F126.
12. Furuse Y, Hashimoto N, Maekawa M, Toyama Y, Nakao A, Iwamoto I, Sakurai K, Suzuki Y, Yagui K, Yuasa S, Toshimori K, Saito Y. 2004. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats. Nephron Exp Nephrol 98:e100-e108.
13. Gartel AL, Radhakrishnan SK. 2005. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65:3980-3985.
14. Gartel AL, Tyner AL. 1999. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 246:280-289.
15. Gilbert RE, Cooper ME. 1999. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 56:1627-1637.
16. Guh JY, Yang ML, Yang YL, Chang CC, Chuang LY. 1996. Captopril reverses high-glucose-induced growth effects on LLC-PK1 cells partly by decreasing transforming growth factor-beta receptor protein expressions. J Am Soc Nephrol 7:1207-1215.
17. Guh JY, Chuang TD, Chen HC, Hung WC, Lai YH, Shin SJ, Chuang LY. 2003. Beta-hydroxybutyrate-induced growth inhibition and collagen production in HK-2 cells are dependent on TGF-beta and Smad3. Kidney Int 64:2041-2051.
18. Hong SW, Isono M, Chen S, Iglesias-de la Cruz MC, Han DC, Ziyadeh FN. 2001. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653-1663.
19. Huang HC, Preisig PA. 2000. G1 kinases and transforming growth factor-beta signaling are associated with a growth pattern switch in diabetes-induced renal growth. Kidney Int 58:162-172.
20. Huang JS, Guh JY, Hung WC, Yang ML, Lai YH, Chen HC, Chuang LY. 1999. Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochem J 342(Pt 1):231-238.
21. Huang JS, Chuang LY, Guh JY, Chen CJ, Yang YL, Chiang TA, Hung MY, Liao TN. 2005. Effect of nitric oxide-cGMP-dependent protein kinase activation on advanced glycation end-product-induced proliferation in renal fibroblasts. J Am Soc Nephrol 16:2318-2329.
22. Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN. 2002. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 296:1356-1365.
23. Kim HW, Kim BC, Song CY, Kim JH, Hong HK, Lee HS. 2004. Heterozygous mice for TGF-betaIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. Kidney Int 66:1859-1865.
24. Koutsodontis G, Moustakas A, Kardassis D. 2002. The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. Biochemistry 41:12771-12784.
25. Kuan CJ, Al-Douahji M, Shankland SJ. 1998. The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy. J Am Soc Nephrol 9:986-993.
26. Lee TH, Chuang LY, Hung WC. 2000. Induction of p21WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells. Oncogene 19:3766-3773.
27. Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY. 2003. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 63:2010-2019.
28. Megyesi J, Price PM, Tamayo E, Safirstein RL. 1999. The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure. Proc Natl Acad Sci USA 96:10830-10835.
29. Milutinovic S, Brown SE, Zhuang Q, Szyf M. 2004. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation. J Biol Chem 279:27915-27927.
30. Pardali K, Kurisaki A, Moren A, ten DP, Kardassis D, Moustakas A. 2000. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. J Biol Chem 275:29244-29256.
31. Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ. 2001. High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-beta 1. Kidney Int 59:1695-1705.
32. Schrijvers BF, De Vriese AS, Flyvbjerg A. 2004. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25:971-1010.
33. Shankland SJ, Wolf G. 2000. Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 278:F515-F529.
34. Sledz CA, Williams BR. 2005. RNA interference in biology and disease. Blood 106:787-794.
35. Terada Y, Inoshita S, Nakashima O, Tamamori M, Ito H, Kuwahara M, Sasaki S, Marumo F. 1999. Cell cycle inhibitors (p27Kip1 and p21CIP1) cause hypertrophy in LLC-PK1 cells. Kidney Int 56:494-501.
36. Thomas MC, Burns WC, Cooper ME. 2005. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 12:177-186.
37. Uenishi H, Eguchi-Ogawa T, Shinkai H, Okumura N, Suzuki K, Toki D, Hamasima N, Awata T. 2007. PEDE (Pig EST Data Explorer) has been expanded into Pig Expression Data Explorer, including 10 147 porcine full-length cDNA sequences. Nucl Acids Res 35:D650-D653.
38. Weinberg WC, Denning MF. 2002. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 13:453-464.
39. Wolf G. 2000. Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 77:S59-S66.
40. Wolf G. 2004. New insights into the pathophysiology of diabetic nephropathy: From haemodynamics to molecular pathology. Eur J Clin Invest 34:785-796.
41. Wolf G, Wenzel UO. 2004. Angiotensin II and cell cycle regulation. Hypertension 43:693-698.
42. Wolf G, Ziyadeh FN. 1999. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405.
43. Yang ML, Guh JY, Yang YL, Chang CC, Chuang LY. 1997. Captopril reverses high glucose-induced effects on LLC-PK1 cells partly by enhancing facilitative glucose transporter messenger RNA expressions. Biochem Mol Biol Int 41:511-519.
44. Zhang Y, Musci T, Derynck R. 1997. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Curr Biol 7:270-276.